A comprehensive study analyzing data from more than 159,000 participants determined which high blood pressure medications and combinations are best tolerated by patients. The research aims to address a major barrier to effective management of high blood pressure: fear of side effects, which often leads patients to stop treatment.
Key takeaways
- Angiotensin receptor blockers (ARBs) are the most well-tolerated class of medications for high blood pressure.
- The combination of an ARB and a calcium channel blocker (CCB) is the best tolerated drug combination.
- CCBs alone are more likely to cause side effects and lead to treatment discontinuation.
Understanding high blood pressure and its treatment
High blood pressure, or High blood pressureIt affects approximately 1.4 billion people globally, a large portion of whom struggle to keep their condition under control. This condition occurs when blood exerts excessive pressure on the walls of the arteries, forcing the heart to work harder and potentially damaging blood vessels and vital organs over time. Effective management usually involves medication and lifestyle changes.
The main medications for high blood pressure include angiotensin II receptor blockers (ARBs), beta blockers, and calcium channel blockers (CCBs). ARBs work by blocking a hormone that constricts blood vessels, allowing them to relax. Beta blockers slow the heart rate and reduce pressure on the walls of blood vessels, while beta blockers prevent calcium from entering the cells of the heart and blood vessels, promoting relaxation.
Although these treatments are available, a large percentage of patients (30% to 80%) stop taking their medications within the first year, often because of side effects such as headache, fatigue, and swollen ankles.
Drug tolerability classification
To clarify the drug’s tolerability, the researchers used a network meta-analysis technique, comparing data from 716 randomized clinical trials. The primary measure was the rate at which patients discontinued treatment due to side effects. Common side effects such as headache, dizziness, swelling, and cough were also tracked.
The study revealed that treatment plans including angiotensin receptor antagonists had the lowest discontinuation rates. Specifically, the combination of ARB and CCB appeared as the most tolerable. Conversely, PCBs used as monotherapy were associated with a higher likelihood of side effects and subsequent withdrawal from treatment.
Interestingly, most blood pressure medications, with the exception of CCBs, were associated with fewer headaches compared to placebo. This is likely because CCBs can cause cerebral vasodilation, which may lead to headaches.
Future implications
These findings, published in JAMA, provide valuable insights for clinicians aiming to personalize hypertension treatment. By better understanding which combinations of medications are better tolerated, healthcare providers can choose medications that patients are more likely to adhere to, ultimately improving long-term blood pressure control. Further long-term studies across diverse populations are recommended to validate these findings for widespread clinical application.
